Scholarlink

Background <p>Bisphosphonates are a mainstay treatment for osteoporosis, with prescribing guidelines based on creatinine clearance (CrCl). However, clinicians often use the estimated glomerular filtration rate (eGFR) from the CKD-EPI equation, which can lead to prescribing discrepancies in older adults, particularly in resource-limited settings where these agents are first-line therapy.</p> Objectives <p>To evaluate the real-world renal safety of bisphosphonates in older adults with discrepant renal function estimates (eGFR ≥ 35 mL/min/1.73&#xa0;m² vs. CrCl &lt; 35 mL/min) and assess renal function changes over 12 months.</p> Methods <p>A retrospective cohort study was conducted in osteoporotic geriatric patients, all of whom had a baseline eGFR between 35 and 60 mL/min/1.73&#xa0;m². These patients were then categorized into two groups based on their calculated CrCl: a CrCl &lt; 35 mL/min group and a CrCl ≥ 35 mL/min group. Renal function was assessed at baseline, month 3, 6 and 12. The primary outcome was the change in renal function over time, analyzed using generalized estimating equations (GEE) with a group × time interaction term.</p> Results <p>A total of 222 patients (190 [85.6%] female; mean age 80.0 ± 6.5 years) were analyzed, with 109 (49.1%) in the CrCl &lt; 35 group and 113 (50.9%) in the CrCl ≥ 35 group. Over the 12-month follow-up, the trajectories of renal function change—as measured by serum creatinine, eGFR, BSA-adjusted eGFR, and CrCl—did not significantly differ between the two groups (all p-values for interaction &gt; 0.05). However, the CrCl &lt; 35 group had a significantly higher adjusted relative risk (RR) of renal-related adverse events at 6 months (adjusted RR 6.77, 95% CI: 1.53 to 29.88) and 12 months (adjusted RR 3.75, 95% CI: 1.04 to 13.50).</p> Conclusions <p>Calculating CrCl is essential before initiating bisphosphonate therapy in older adults. While long-term renal function trajectories were stable, the increased risk of acute adverse events in patients with CrCl &lt; 35 mL/min underscores the need for careful monitoring. These findings suggest that bisphosphonates may be used cautiously in selected patients with impaired renal function, especially in resource-limited settings.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The effect of bisphosphonates on kidney function in osteoporotic geriatric patients with impaired renal function

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月23日

查看全文
  • Akarawin Tweekittikul,
  • Varalak Srinonprasert,
  • Unchana Sura-amonrattana

摘要

Background

Bisphosphonates are a mainstay treatment for osteoporosis, with prescribing guidelines based on creatinine clearance (CrCl). However, clinicians often use the estimated glomerular filtration rate (eGFR) from the CKD-EPI equation, which can lead to prescribing discrepancies in older adults, particularly in resource-limited settings where these agents are first-line therapy.

Objectives

To evaluate the real-world renal safety of bisphosphonates in older adults with discrepant renal function estimates (eGFR ≥ 35 mL/min/1.73 m² vs. CrCl < 35 mL/min) and assess renal function changes over 12 months.

Methods

A retrospective cohort study was conducted in osteoporotic geriatric patients, all of whom had a baseline eGFR between 35 and 60 mL/min/1.73 m². These patients were then categorized into two groups based on their calculated CrCl: a CrCl < 35 mL/min group and a CrCl ≥ 35 mL/min group. Renal function was assessed at baseline, month 3, 6 and 12. The primary outcome was the change in renal function over time, analyzed using generalized estimating equations (GEE) with a group × time interaction term.

Results

A total of 222 patients (190 [85.6%] female; mean age 80.0 ± 6.5 years) were analyzed, with 109 (49.1%) in the CrCl < 35 group and 113 (50.9%) in the CrCl ≥ 35 group. Over the 12-month follow-up, the trajectories of renal function change—as measured by serum creatinine, eGFR, BSA-adjusted eGFR, and CrCl—did not significantly differ between the two groups (all p-values for interaction > 0.05). However, the CrCl < 35 group had a significantly higher adjusted relative risk (RR) of renal-related adverse events at 6 months (adjusted RR 6.77, 95% CI: 1.53 to 29.88) and 12 months (adjusted RR 3.75, 95% CI: 1.04 to 13.50).

Conclusions

Calculating CrCl is essential before initiating bisphosphonate therapy in older adults. While long-term renal function trajectories were stable, the increased risk of acute adverse events in patients with CrCl < 35 mL/min underscores the need for careful monitoring. These findings suggest that bisphosphonates may be used cautiously in selected patients with impaired renal function, especially in resource-limited settings.